BackSino Biopharmaceutical Limited Overview

Sino Biopharmaceutical Limited EBIT

Latest ebit for 1177.HK: $9.5B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$3.31B
↑ 93.98% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

$9.49B
↑ 85.89% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Sino Biopharmaceutical Limited (1177.HK) FAQ

The latest EBIT for 1177.HK is $9.5B as of June 2026. That compares with $5.1B in the prior-year period — up 85.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Sino Biopharmaceutical Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1177.HK's EBIT moved from $5.1B to $9.5B — a 85.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sino Biopharmaceutical Limited's operating scale or balance-sheet position.

Against Healthcare companies, 1177.HK currently prints $9.5B for EBIT, while the sector average sits near $1.9T. That is roughly 99.5% below the sector mean. Large gaps often invite a closer look at Sino Biopharmaceutical Limited's growth, margins, and balance sheet.

A EBIT figure of $9.5B for 1177.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 1177.HK's EBIT ($9.5B), review year-over-year change from $5.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.